Cascade Submissions at Medical Journals: What Transfer Offers Mean for Authors in 2026

The rejection email arrives, and buried below the standard language is an offer: the journal thinks your manuscript might be a good fit for another title in their portfolio, and they can transfer everything over automatically. Most authors who have submitted to Nature, Lancet, JAMA, or the journals published by Elsevier, Springer Nature, and Wiley have seen this message. For a long time, the calculation was simple. If the receiving journal looked credible and the transfer was free, you clicked accept and saved a few hours of re-formatting.

The calculation is no longer that simple. Over the past eighteen months, major funders have introduced restrictions on article processing charges that directly affect which journals you can publish in under your grant. HHMI banned hybrid APC payments in January 2026. Cancer Research UK withdrew all APC funding in April 2026. NIH has a proposal in review that would cap reimbursable APCs at between $2,000 and $6,000 per article. When the journal that emerges from a cascade recommendation carries an APC above your funder's cap, or is a gold open-access title that your funder's waivers do not cover, the transfer can move your manuscript from one problem to a different, more expensive one.

Understanding how these systems work, what actually travels with your manuscript, and when to decline is now a practical skill for any medical researcher who submits regularly to major journals.

How Cascade Systems Were Built and Why

Large academic publishers built transfer systems for two overlapping reasons. One is author convenience. Resubmitting to a second journal requires re-uploading files, re-entering author affiliations, reformatting references, and often rebuilding submission forms from scratch. Transfer services eliminate most of that friction. The other reason is portfolio utilization. When a high-rejection journal like Nature Medicine or The Lancet declines a manuscript, the publisher would prefer that the paper remain within their ecosystem rather than migrate to a competitor. A transfer to Nature Communications or a Lancet regional title keeps the submission data and, potentially, the paper within Springer Nature or Elsevier.

Elsevier calls its system the Article Transfer Service. When an Elsevier journal editor determines that a manuscript is not the right fit for the original journal but could suit another Elsevier title, the editor can trigger a transfer invitation. The author then receives an offer with one or more journal suggestions, and accepting initiates an automatic file transfer. Springer Nature operates what it calls the Transfer Desk, which analyzes the subject area of the originating journal and the manuscript's assigned subject terms to generate a ranked list of receiving journals. The service is described as free and typically produces recommendations within one working day. Nature Portfolio's transfer system works similarly: after a rejection, authors can access a transfer link that routes them to a list of suggested journals within the portfolio, with automatic file transfer for most cases. Wiley offers comparable infrastructure across its journal network, as do BMC and Taylor and Francis.

The systems vary in their sophistication, but the underlying structure is the same across publishers. An algorithm matches the manuscript's metadata, subject terms, and sometimes abstract keywords against the receiving journals in the portfolio, ranks them by apparent fit, and presents the list to the author. What the algorithm optimizes for is not always obvious. Portfolio utilization and open access uptake are both plausible factors, alongside subject match.

What Transfers with Your Manuscript

In most systems, the manuscript files transfer automatically: the main document, supplementary materials, cover letter, and the metadata you entered at submission (author list, affiliations, corresponding author details, keywords, article type). This saves anywhere from thirty minutes to two hours of re-entry work, depending on how many authors are on the paper and how complex the submission system is.

Peer review reports are a separate matter. When reviewer reports transfer, it can significantly speed up the editorial process at the receiving journal. The editor may use existing reports to inform their initial assessment, may ask the same reviewers to provide an updated opinion, or may send the manuscript to entirely new reviewers. None of this is guaranteed. Reviewer report transfer generally requires the explicit consent of each reviewer, and in practice many reviewers decline. When reviewer consent is not obtained or is declined, the receiving journal typically starts a fresh review. Elsevier's documentation notes that reviewer reports are transferred only when permitted by reviewer consent. Springer Nature's Transfer Desk describes a similar conditional approach.

One thing that does not transfer is acceptance. The receiving journal remains editorially independent and will make its own decision. In some cases, a manuscript transferred from a high-impact journal to a lower-tier title in the same portfolio still receives a desk rejection because the subject does not fit the second journal's scope either, or because the paper has fundamental problems that the transfer system could not assess.

Authors should also verify whether the transfer resets the manuscript's submission date for the purposes of priority claims or preprint embargo policies. Most systems treat the transfer as a new submission at the receiving journal, with a new submission timestamp.

The Portfolio Hierarchy and What It Means for Medical Papers

Most cascade systems route manuscripts toward journals that sit below the originating journal in a portfolio hierarchy. A rejection from Nature Medicine tends to surface recommendations for Nature Communications, Communications Medicine, or one of the npj-branded journals. A rejection from The Lancet might route toward eClinicalMedicine, The Lancet Regional Health titles, or PLOS Medicine if the Lancet-PLOS relationship is being leveraged. A rejection from a flagship Elsevier clinical journal might cascade toward a more specialized Elsevier title or toward one of its high-volume open access outlets.

This hierarchy is not inherently problematic. Nature Communications publishes rigorous work across all scientific fields, and eClinicalMedicine has established itself as a serious clinical journal with MEDLINE indexing and a growing impact factor. The issue arises when authors assume that a transfer recommendation constitutes editorial endorsement by the originating journal. It does not. The algorithm that generates the recommendation does not know whether your study has a control group, whether your statistics were reviewed internally, or whether the clinical implication you are drawing is supported by the effect size. It knows the subject area and the journal's listed scope.

For medical research specifically, scope match matters more than it might in basic science. A clinical trial in a specific disease area may not belong in a generalist open science journal simply because both appear in the same publisher's portfolio. A retrospective cohort study from a clinical specialty might be rejected by a specialty journal and cascaded toward a general clinical science title whose audience has no particular interest in the specific condition or intervention. Transferring without considering whether the new audience is the one who needs to read your paper is the cascade trap that catches a lot of authors.

The APC Problem That Changed in 2026

For researchers whose grants include open access publishing funds, cascade transfers to gold open access journals have always carried an APC. What changed over the past year is that multiple major funders simultaneously restricted how much of that APC they will cover, and under what conditions.

HHMI ended its support for hybrid open access APCs in January 2026. Hybrid journals are subscription journals that offer authors a paid open access option. Many of the mid-tier journals that appear in Springer Nature and Elsevier cascade recommendations are hybrid titles. If you are at an HHMI-funded institution and a transfer routes you to a hybrid journal, HHMI will not fund the APC. You are either publishing behind a paywall or paying out of pocket or institutional funds. Cancer Research UK went further in April 2026, withdrawing all APC support, meaning researchers funded by CRUK cannot use their grants to pay APCs at any journal, hybrid or gold. NIH's proposed APC cap, if finalized, would set a ceiling that some prominent gold OA journals already exceed.

Institutional transformative agreements have partly softened this pressure for authors at universities with active Read and Publish deals. If your institution has a current agreement with the publisher, many APCs are covered under the agreement rather than charged separately. But these agreements are not universal, they are not permanent, and the receiving journal has to fall within the agreement's scope. Before accepting a cascade, checking whether your institution's library has a current transformative agreement that covers the receiving journal is the single most useful financial due diligence step.

Evaluating the Receiving Journal

Assuming the APC question is resolved, the next layer of evaluation is whether the receiving journal is actually appropriate for your paper and your career. Several practical questions apply here that do not appear in the transfer offer email.

Indexing is the starting point. Is the receiving journal indexed in MEDLINE/PubMed? For clinical research, PubMed indexing determines discoverability within the medical community and eligibility for inclusion in systematic reviews. A journal that is indexed in Web of Science or Scopus but not in MEDLINE may be appropriate for a basic science paper but is a meaningful step down in visibility for clinical research. If the receiving journal is not in PubMed, that is something to weigh consciously rather than discover six months after acceptance.

Impact factor and quartile matter for some career contexts and do not for others. Junior researchers applying for clinical academic positions in systems that weight publication metrics need to assess whether the receiving journal's JCR quartile aligns with what their department or funding body counts. Researchers in systems that use narrative assessment or have moved toward responsible research metrics may care less. Either way, looking up the journal in the current JCR data before accepting takes five minutes and removes uncertainty.

Editorial stability is worth a brief check. A small number of journals offered in cascade recommendations have experienced the kind of editorial board resignations or ownership changes that have recently destabilized several once-credible titles. If the receiving journal is one you have never heard of, spending five minutes verifying its publisher, editorial board composition, and COPE membership is reasonable due diligence. The Scopus and Web of Science delisting waves of 2025 and 2026 have caught some journals that previously appeared in portfolio recommendations.

When a Transfer Makes Sense

There are clear situations where accepting a cascade transfer is the right move. The most straightforward is when the original rejection was a scope decision, not a quality decision. If the editor's rejection letter indicates that the manuscript is well-conducted but outside the scope of the journal's current focus, and the receiving journal's scope genuinely aligns with your study's population, intervention, and outcome, a transfer can place the paper where it belongs faster than starting from scratch.

Reviewer report continuity is another legitimate advantage. If the original journal had your paper in full review and the rejection came with substantive reviewer comments, those reports transferring to the receiving journal (with reviewer consent) gives the new editor immediately useful signal. In some cases, editors at the receiving journal will make a decision on revision rather than sending out for fresh review, which can meaningfully compress the timeline.

If the APC is covered by a transformative agreement or waiver and the receiving journal is indexed and credible, and the scope matches, the time saved by not reformatting and re-uploading is real. For a complex clinical paper with many authors and supplementary datasets, re-submission from scratch can take a full working day. That's worth something.

When to Decline and Resubmit Independently

Declining a transfer offer is always an option, and there are several conditions under which it is the better choice.

If the rejection came with substantive reviewer criticism of the study design, analysis, or conclusions, transferring before addressing those issues sends the same problem to a new editor. The reviewer reports may follow the manuscript. Even if they do not, a paper with unaddressed methodological weaknesses will encounter the same concerns at the next journal. The time saved by a transfer is not worth receiving a second rejection for the same reasons as the first. Revise before submitting anywhere.

If the receiving journal's APC is incompatible with your funding situation, declining is financially straightforward. The portfolio recommendation algorithm does not check your grant terms. It does not know whether you are an HHMI investigator, a CRUK-funded clinical scientist, or an NIH-funded researcher whose institute has its own APC policy interpretations. That information lives with you, not with the transfer system.

If the receiving journal is outside your field's primary readership, the paper may be technically published while remaining effectively invisible to the clinicians or researchers who need to read it. A study on emergency medicine outcomes published in a general science megajournal may not reach the emergency medicine community in the same way it would through Annals of Emergency Medicine or Resuscitation. Publication in the right venue for your audience sometimes matters more than faster publication in a convenient venue.

When you decline, you retain full freedom to resubmit where you choose. The rejection from the original journal does not obligate you to stay within that publisher's portfolio. Many authors who decline cascade offers go on to submit to journals outside the portfolio and achieve a better fit for the paper.

The Third Option: Directing Your Own Transfer

Some publishers give authors more control than others over which journal receives the transfer. Springer Nature's Transfer Desk, for instance, provides a list of ranked recommendations and then lets authors specify their preferred destination from that list, or in some cases request an alternative title within the portfolio. This is more useful than a single-destination transfer link because it allows you to bypass the algorithm's first recommendation if a different journal in the portfolio is actually the better fit.

In these systems, the time savings of the transfer service remain available even if you do not take the top recommendation. Authors sometimes overlook this because the transfer email presents a default option prominently. Reading the full offer before responding often reveals more flexibility than the headline journal name suggests.

If the publisher offers a list and none of the journals on it are genuinely appropriate, declining the transfer while taking note of the listed journals is still useful information. Those are the titles the publisher's algorithm associates with your manuscript. If you independently decide to submit to one of them later, you know the file preparation required.

Cover Letter Revision Is Not Optional

One consistent mistake in cascade submissions is transferring the cover letter unchanged. The cover letter from your original submission was written for that journal's editorial priorities, scope, and readership. It probably references why the paper fits the original journal's mission or a gap in that journal's recent coverage. Sending that letter to a different journal, even within the same publisher, is at best irrelevant and at worst signals that the author did not think carefully about the transfer.

Most transfer systems flag the cover letter as author-editable before the transfer is finalized. Take the time to revise it. Address the new journal's scope explicitly. If you can reference recent work the new journal has published in an adjacent area, do so. If the original rejection letter gave any positive signals about the work's quality or novelty, you may reference that the paper originated from a submission to the first journal, without quoting the rejection in detail.

The manuscript itself may also benefit from minor revision before transfer. If reviewer reports accompanied the rejection and identified specific weaknesses, addressing the most straightforward ones before the manuscript arrives at the new journal strengthens your position even if the new editor obtains fresh reviews. It also signals that the authors have engaged actively with feedback, which reviewers at the receiving journal will appreciate if they see the prior reports.

What the Transfer Decision Actually Reflects

Cascade offers have become common enough that receiving one is not a judgment on your paper's quality. High-rejection journals like NEJM, The Lancet, and JAMA decline the majority of submissions, including many that are published elsewhere with significant impact. The cascade offer from those journals reflects a policy decision about fit and volume, not necessarily a statement about the scientific merit of your work.

That said, the decision you make after receiving the offer does reflect on your submission strategy. Authors who transfer without reviewing the receiving journal, without checking their APC situation, and without revising their cover letter are making a passive choice in a process that rewards active evaluation. The time saved by not re-uploading files is roughly fifteen to sixty minutes. The consequences of publishing in a journal that does not reach your intended audience, or that requires an APC your institution cannot support, extend well beyond a single afternoon.

In 2026, with funders actively restricting how open access publishing can be funded, this evaluation is more consequential than it was two or three years ago. The systems publishers built to make transfers frictionless have not kept pace with the policy environment researchers now navigate. That gap is the author's responsibility to close, one offer at a time.

Further Reading